Seagen Inc. - Common Stock (NQ:SGEN)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Seagen Inc. - Common Stock

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

European Commission Approves PADCEV™ (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer

April 13, 2022

From Seagen Inc.

Via Business Wire

Seagen Wins $42M Patent Claim Against Daiichi In Cancer Drug Case ↗

April 11, 2022

A jury in Marshall, Texas, awarded Seagen Inc (NASDAQ: SGEN)

Via Benzinga

Seagen Announces Jury Award in Patent Infringement Case Against Daiichi Sankyo

April 08, 2022

From Seagen Inc.

Via Business Wire

Seagen to Highlight Preclinical Data for Enfortumab Vedotin and Two Novel Antibody-Drug Conjugates at AACR Annual Meeting

April 08, 2022

From Seagen Inc.

Via Business Wire

What 7 Analyst Ratings Have To Say About Seagen ↗

February 10, 2022

Seagen (NASDAQ:SGEN) has observed the following analyst ratings within the last quarter:

Via Benzinga

Seagen to Host Conference Call and Webcast Discussion of First Quarter 2022 Financial Results on April 28, 2022

April 07, 2022

From Seagen Inc.

Via Business Wire

Good Entry Point for Biotech Stocks ↗

April 04, 2022

Life science and biotech stocks had a good week with the most well-known ETFs up 3-4% for the week and off recent bottoms.

Via Talk Markets

Top Nasdaq 100 Stocks: Trading Opportunities For Next Week ↗

April 03, 2022

A security pattern traces the distinct movements of security prices that, once recognized, help traders to make informed trading decisions. Let's look at some Nasdaq 100 stock opportunities by...

Via Talk Markets

10 Health Care Stocks Whale Activity In Today's Session ↗

March 17, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Sanofi, Seagen Collaborate For Antibody-Drug Conjugates Against Cancer Targets ↗

March 16, 2022

Via Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study ↗

March 16, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Seagen and Sanofi Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates

March 16, 2022

From Seagen Inc.

Via Business Wire

Tough Slogging Ahead for Investors, Diversification is Important ↗

March 07, 2022

Speculative small/mid-cap biotech stocks hit new lows this past week with the XBI at a “triple bottom” about the $84 level only 10 points above the March 2020 lows.

Via Talk Markets

Astellas and Seagen Announce CHMP Confirms Positive Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer

February 28, 2022

From Seagen Inc.

Via Business Wire

Seagen and Genmab Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma

February 24, 2022

From Seagen Inc.

Via Business Wire

Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma

February 24, 2022

From Genmab A/S

Via Business Wire

Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them? ↗

February 17, 2022

Can the formerly red-hot biotech segment return to its previous glory?

Via Investor's Business Daily

Astellas Pharma - Seagen's Enfortumab Shows 36% Pathologic Complete Response In Bladder Cancer Patients ↗

February 15, 2022

Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) announced the initial results from Cohort H of the EV-103 trial investigating PADCEV (...

Via Benzinga

Seagen and Astellas Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy

February 14, 2022

From Seagen Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

February 11, 2022

Gainers Dermata Therapeutics (NASDAQ:DRMA) shares moved upwards by 26.6% to $1.35 during Friday's regular session. As of 12:30 EST, Dermata Therapeutics's stock is...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

February 11, 2022

Gainers Dermata Therapeutics (NASDAQ:DRMA) stock rose 29.0% to $1.38 during Friday's pre-market session. The company's market cap stands at $11.4 million. Innoviva...

Via Benzinga

Netflix And Sirius XM Lead The Nasdaq Sharply Lower ↗

February 10, 2022

U.S. indices were trading lower Thursday following comments from St. Louis Fed President James Bullard indicating he favors a 1% rate increase by J...

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

February 10, 2022

On Thursday, 89 companies hit new 52-week lows. Noteable 52-Week Lows: The company with the largest market cap to set a new 52-week low was Seagen (NASDAQ:SGEN)....

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

February 10, 2022

Gainers Dermata Therapeutics (NASDAQ:DRMA) shares moved upwards by 26.1% to $1.35 during Thursday's regular session. The current volume of 17.5 million shares is 7266....

Via Benzinga

Seagen Crumbles With AstraZeneca Expected To Pressure Its New Drug ↗

February 10, 2022

Seagen called for lower-than-expected 2022 sales of Tukysa, a breast cancer drug.

Via Investor's Business Daily

The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly ↗

February 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

10 Biggest Price Target Changes For Thursday ↗

February 10, 2022

Macquarie boosted the price target on Twilio Inc. (NYSE: TWLO) from $281 to $306. Twilio shares jumped 20.4% to $243.23 in pre-market trading.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

February 10, 2022

Gainers Dermata Therapeutics (NASDAQ:DRMA) stock moved upwards by 27.1% to $1.36 during Thursday's pre-market session. The company's market cap stands at $11.3...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

February 10, 2022

Good morning, trader! Rub that sleep out our your eyes because we're going over the biggest pre-market stock movers for Thursday!

Via InvestorPlace

Why Are Seagen Shares Sinking Today? ↗

February 10, 2022

Seagen Inc (NASDAQ: SGEN) reported Q4 revenues

Via Benzinga

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.